Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Mauritius.
Press releases published on October 17, 2025
Artios Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025
Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals Results support the potential advancement of ART6043 into …
Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were presented for the first time at ESMO 2025. Confirmed response by …
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows triplet therapy with ciforadenant, ipilimumab and nivolumab …
InboxAlly Unveils Expert-Developed 15-Step Pre-Send Email Marketing Checklist to Eliminate Costly Mistakes
New York, NY , Oct. 17, 2025 (GLOBE NEWSWIRE) -- InboxAlly, the market’s leading deliverability solution trusted by agencies, enterprises, and high-volume senders worldwide, today introduced its 15-Step Pre-Send Email Marketing Checklist authored by …
Protext Mobility, Inc. (OTC: TXTM) Announces Plans for Corporate Website Redesign and Investor Relations Suite to Enhance Transparency and Shareholder Engagement
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM), an emerging leader in botanical-based biotechnology, today announced its strategic initiative to redesign its corporate website and develop a dedicated Investor Relations (IR) …
fullthrottle.ai® Launches the Industry’s First Generative AI-Powered Automotive DSP Advancing Tierless Automotive Marketing Using Patented First-Party Household Identity
Built on top of the new fullthrottle.ai self-service platform, the new offering unifies audience creation, omnichannel activation, and real-time attribution across dealers, dealership groups and OEM’s PHILADELPHIA, Oct. 17, 2025 (GLOBE NEWSWIRE) -- …
Fast track to career success: CIAT and CompTIA offer innovative tech training and certification program
NATIONAL CITY, Calif. and DOWNERS GROVE, Ill., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Future technology professionals can get a jump start on their career plans with an assist from California Institute of Applied Technology (CIAT) and CompTIA. CIAT announced …
LiquidTrust’s Protected Pay Named Silver Medalist in 2025 Datos Impact Awards in Commercial Banking & Payments
Los Angeles, CA, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Datos Insights, the leading research and advisory partner to the banking, insurance, and securities industries, has recognized LiquidTrust™, a B2B payments solutions provider that partners with financial …
Vocodia Holdings Corp. and Scale Agile Solutions Announce Letter of Intent for Strategic Asset Acquisition
BOCA RATON, Fla., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vocodia Holdings Corp. (OTC: VHAI) (“Vocodia”), a leader in conversational AI solutions, and AdRetreaver LLC d/b/a Scale Agile Solutions (SAS), a provider of innovative AI-driven technologies, today …
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …
Great Estate Blockchain (OTC: VAYK) to Launch Solution Unlocking $1 Trillion Dormant Asset
ATLANTA, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Great Estate Blockchain, Inc. (OTC: VAYK), formerly known as Vaycaychella, Inc., today announced the completion of its name change and the launch of a platform designed to unlock and monetize the intangible value …
OBOOK Holdings Inc. Announces Successful Direct Listing on Nasdaq
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- OBOOK Holdings Inc. (NASDAQ: OWLS) ("OBOOK" or the "Company"), a blockchain technology company operating as the OwlTing Group, announced the successful direct listing of its Class A common shares on the Nasdaq …
24/7 Market News- Kraig Labs Spider Silk Poised to Lead the Sustainable Textile Revolution
DENVER, Oct. 17, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that, as the fashion industry confronts mounting pressure to overhaul its wasteful …
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
BiomX believes that it has fully addressed the FDA’s queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical clarifications on the nebulizer has also been addressed In …
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and …
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-up Immune activation observed in all patients with 81% of EVX-01’s vaccine …
IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
Company seeks strategic partners to advance novel PlaCCine technology LAWRENCEVILLE, N.J., Oct. 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating …
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Committee for …
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular …